X
[{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,080.0 million","upfrontCash":"$60.0 million","newsHeadline":"Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 to Treat Elevated Lipoprotein at American Heart Association 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence\u2019s mRNAi GOLD\u2122 Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,024.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silence Therapeutics to Buyback siRNA Complement Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$4,080.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Silence Therapeutics Announces Oversubscribed $120 Million Private Placement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Silence Therapeutics
Filters
Companies By Therapeutic Area
Details:
SLN360 (zerlasiran) is a phase 2 investigational siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.
Lead Product(s):
Zerlasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMarch 13, 2024
Details:
Through collaboration, Silence and AstraZeneca will initiate clinical trial studies by using Silence’s proprietary mRNAi GOLD platform to develop siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases.
Lead Product(s):
mRNAi-based Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator:
AstraZeneca
Deal Size: $570.0 millionUpfront Cash: $80.0 million
Deal Type: CollaborationFebruary 23, 2024
Details:
The company intends to use the net proceeds for the advancement of its ongoing clinical development for SLN360 (zerlasiran) for the treatment of atherosclerotic cardiovascular disease.
Lead Product(s):
Zerlasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
5AM Ventures
Deal Size: $120.0 millionUpfront Cash: Undisclosed
Deal Type: Private PlacementFebruary 05, 2024
Details:
SLN360 (zerlasiran) is a siRNA (short interfering RNA) designed to lower the body’s production of lipoprotein(a), a key genetic risk factor for cardiovascular disease.
Lead Product(s):
Zerlasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableNovember 01, 2023
Details:
The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.
Lead Product(s):
siRNA
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator:
Hansoh Pharma
Deal Size: $1,316.0 millionUpfront Cash: $16.0 million
Deal Type: CollaborationJuly 11, 2023
Details:
Under the agreement, Silence and AstraZeneca is focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
Lead Product(s):
siRNA Therapeutic
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator:
AstraZeneca
Deal Size: $4,080.0 millionUpfront Cash: $80.0 million
Deal Type: CollaborationMay 04, 2023
Details:
Silence will gain rights back to 2 undisclosed complement targets. SLN501, the C3 targeting program will remain under the agreement. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver.
Lead Product(s):
siRNA-based Drug
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Recipient:
Mallinckrodt Pharmaceuticals
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: AgreementMarch 28, 2023
Details:
SLN360 is a gene ‘silencing’ therapy, designed to temporarily blocks LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). As the levels of Lp(a) are lowered, which lowers the risk of heart diseases, heart attacks and strokes.
Lead Product(s):
SLN360
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableJanuary 12, 2023
Details:
SLN360, is gene silencing therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect.In this case, it aims to ‘silence’ LPA, a gene that tells body to make a specific protein that is only found in Lp(a).
Lead Product(s):
SLN360
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableNovember 04, 2022
Details:
Silence and Hansoh entered a collaboration to develop siRNAs leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the rest two targets in all territories except the China region.
Lead Product(s):
SLN-HAN-1
Therapeutic Area: Technology Product Name: SLN-HAN-1
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator:
Hansoh Pharma
Deal Size: $1,316.0 millionUpfront Cash: $16.0 million
Deal Type: CollaborationApril 25, 2022
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
